Selpercatinib

In this article, we will discuss about Selpercatinib (Dosage Overview). So, let’s get started.

Indications

Selpercatinib (RETEVMO™) is a kinase inhibitor indicated for the treatment of:
• Adult patients with metastatic RET fusion-positive non-small cell lung
cancer (NSCLC).
• Adult and pediatric patients 12 years of age and older with advanced or
metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
• Adult and pediatric patients 12 years of age and older with advanced or
metastatic RET fusion-positive thyroid cancer who require systemic
therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Dosage

• Select patients for treatment with Selpercatinib (RETEVMO™) based on the presence of a RET gene fusion (NSCLC or thyroid) or specific RET gene mutation (MTC).
• Recommended dosage in adults and pediatric patients 12 years of age or
older is based on weight:
• Less than 50 kg: 120 mg orally twice daily
• 50 kg or greater: 160 mg orally twice daily
• Reduce Selpercatinib (RETEVMO™) dose in patients with severe hepatic impairment.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.